Biotech & Pharma.T.A, Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A,

BIB 77.80

-3.5%

Dec 9 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (1985)	11/6/2007 9:13:38 PM
From: Jibacoa	Read Replies (1) of 3722

SQNM was up 11.57% & continued to do OK AHs.The volume was 200Ks above its ADV. bigcharts.marketwatch.com The stock closed at its intraday H & is starting to get off its near term DT coming from the )ct 17 H at 11.63 bigcharts.marketwatch.com SQNM will start tomorrow morning a workshop at the AMP meeting in los Angeles & is going to have an exhibition booth to provide information about its MassARRAY products & genomics analysis capabilities. I think I better buy back the shares that I had to sell because of my protective SL last month.<g> It also has announced that it will market its licensed nucleic acid-based technology under the brand “SEQureDx" & is making plans to commercialize its molecular diagnostic tests based on that technology for screening and detection of prenatal disorders like Rhesus D incompatibility, Fragile X, Hemophilia, & a test for common anueploidies, like Downs syndrome. The workshop, “Introducing the Dawn of a New Technology: Noninvasive Prenatal Diagnostics,” will be hosted by Steve Owings, V.P. for Commercial Development of Prenatal Diagnostics, & will include the following presentations: Fetal Nucleic Acids in Maternal Plasma as a New Platform for Noninvasive Prenatal Diagnosis Extraction & Enrichment Methods for Fetal DNA MassARRAY Technology: Past and Future Applications in Genetic Testing Strategies for Successful Noninvasive Prenatal Testing: Fetal Identifiers and Workshop Summary SQNM is building a menu of prenatal tests with this technology, and expects the near-term commercial introduction of the first laboratory test to detect Rh incompatibility.It also will provide an update on its strategy for a noninvasive detection of Down syndrome. If the stock can close above $11 tomorrow, it should be a ble to resume its Sep-Oct UT, but don't expect another double that fast.<g> bigcharts.marketwatch.com Although the long term chart still looks "interesting" & it certainly has plenty of room to run.<g> bigcharts.marketwatch.com Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next